X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antroquinonol
Therapeutic Area: Infections and Infectious Diseases Product Name: Hocena
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
Antroquinonol® has shown anti-viral, anti-inflammatory and anti-fibrotic characteristics in past animal studies, suggesting high likelihood in becoming successful treatment option for coronavirus-induced pneumonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant S-2P antigen,CpG 1018,Aluminum Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: MVC-COV1901
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
First participant has been dosed in the Phase 2 clinical trial evaluating MVC’s COVID-19 vaccine candidate, MVC-COV1901. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
